Wordt geladen...
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
BACKGROUND: Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). METHODS: We mined...
Bewaard in:
| Gepubliceerd in: | Cardiovasc Diabetol |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7879696/ https://ncbi.nlm.nih.gov/pubmed/33573667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01243-4 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|